Non Insulin Dependent Diabetes, Type 2 Diabetes
Conditions
Keywords
Continuous glucose monitoring, Primary care, Diabetes management
Brief summary
The goal of this clinical trial is to learn if periodic use of over-the-counter continuous glucose monitoring (CGM) can support glucose management in people with type 2 diabetes not using insulin being treated in primary care settings. The main questions it aims to answer are: * Is periodic use of CGM every 30 or 90 days for six months associated with reduced A1C compared to usual care at baseline? * Is periodic use of CGM every 30 or 90 days for six months associated with increased time in range and time in tight range compared to usual care at baseline? * Is periodic use of CGM every 90 days over six months associated with non-inferior A1C reduction compared to periodic use of CGM every 30 days? * Are clinician feasibility and acceptability of periodic, OTC CGM higher than for prescription CGM? * How acceptable is periodic, OTC CGM to people with non-insulin-treated type 2 diabetes? Researchers will compare use of periodic CGM every 30 and 90 days to see if less frequent periodic CGM use can support glucose management as effectively as more frequent use. Participants will: * be assigned to one of two groups using the 15-day Dexcom Stelo® glucose biosensor every 30 or 90 days over a six-month period. * receive Stelo devices every 30 or 90 days (as randomized) * complete up to 9 virtual or in-person visits with the study team. * complete 3 fingerstick A1c tests. * wear a blinded CGM device at 3 time points outside of Dexcom Stelo® use. * complete a survey at the end of the study.
Interventions
DEVICEPeriodic, over-the-counter continuous glucose monitoring
Periodic, over-the-counter continuous glucose monitoring for people with non-insulin-treated type 2 diabetes treated in primary care settings.
Sponsors
University of Colorado, Denver
American Diabetes Association
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years at time of enrollment 2. Diagnosis of type 2 diabetes 3. Able to read and understand English (Dexcom Stelo is currently only available in English) 4. No real-time or intermittently scanned (Flash) CGM use 12 months prior to enrollment 5. Stable medication regimen (medication classes) and dose (equivalent dose if medication has been changed within the same medication class) for any glucose lowering or weight loss medications for 30 days prior to enrollment and willing to not change medications prior to randomization unless safety concerns. 6. Cell phone meeting minimum required OS compatibility with Stelo 7. Willing to use the study device and download the Stelo app 8. Willing and able to complete all study procedures per investigator discretion, including willingness to accept either experimental group (q30 or q90). 9. A1C value (from lab data or chart review) greater than or equal to 6.5 in the 6 months prior to enrollment 10. Currently receiving primary care in a participating study practice
Exclusion criteria
1. Use of insulin in the 12 months prior to screening or planning to initiate insulin during the next 12 months (short-term use of insulin in an inpatient setting is acceptable) 2. Concomitant disease or condition that in the opinion of the investigator may compromise patient safety including but not limited to severe mental illness, a diagnosed or suspected eating disorder, or any uncontrolled or chronic medical condition that would interfere with study related tasks or visits 3. Use within 30 days of screening visit of any medication that in the opinion of the investigator may exacerbate glucose dysfunction (e.g. systemic corticosteroids) 4. Current or planned use of hydroxyurea (due to interference with CGM) 5. Known presence of a hemoglobinopathy or other condition that is expected to affect the measurement of A1C in the judgment of the investigator 6. Known severe allergy to medical grade adhesive, a serious skin condition that could interfere with CGM placement, or extensive tattoos that precludes the use of CGM in an FDA approved location 7. End stage renal disease currently managed by dialysis or eGFR \<30 mL/min/1.73m2 8. Current participation in another interventional study protocol that could impact participation in this study per investigator discretion 9. Pregnant or planning to become pregnant within the next 6 months. 10. Planning to switch primary care practices in the next 6 months.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in A1C from baseline to 6 months | From enrollment to completion of study visits at 6 months | Change in A1C from baseline (enrollment) to 6 months. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Time in Range from baseline to 6 months | From enrollment to the completion of study visits at 6 months. | Change in time in range (TIR) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months. |
| Change in Time in Tight Range from baseline to 6 months | From enrollment to the completion of study visits at 6 months. | Change in time in tight range (TITR) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months. |
| Change in mean glucose from baseline to 6 months | From enrollment to the completion of study visits at 6 months. | Change in mean glucose collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months. |
| Change in TAR (>180) from baseline to 6 months | From enrollment to the completion of study visits at 6 months. | Change in time above range (\>180 mg/dL) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to completion of study visits at 6 months. |
| Change in A1C from baseline to 3 months. | From enrollment to 3-month study visit | Change in A1C from baseline (enrollment) to 3 months. |
| Change in TIR from baseline to 3 months. | From enrollment to 3-month study visit | Change in TIR from baseline (enrollment) to 3 months. |
| Change in TITR from baseline to 3 months. | From enrollment to 3-month study visit | Change in TITR from baseline (enrollment) to 3 months. |
| Change in mean glucose from baseline to 3 months | From enrollment to 3-month study visit | Change in mean glucose collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to the 3-month study visit. |
| Change in TAR (>180) from baseline to 3 months | From enrollment to 3-month study visit | Change in time above range (\>180 mg/dL) collected from patients via blinded Dexcom G7 continuous glucose monitoring from baseline (enrollment) to 3-month study visit. |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORTamara Oser, MD
University of Colorado Denver Anschutz Medical Campus
Outcome results
None listed